Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Salvador Peron

Urology Toledo, OH Medical Doctor

NPI 1881691640 CMS profile 357698

3436 Granite Cir, Toledo, OH 43617

Open in the dashboard

General payments

$14,126

297 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

3 holdings reported · through program year 2025

Through program year 2025, Salvador Peron of Toledo, OH is reported in the CMS Open Payments database as having received $14,126 across 297 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,780 37
2024 General $3,160 33
2023 General $965 38
2022 General $2,605 51
2021 General $2,564 53
2020 General $600 36
2019 General $2,452 49
2021 Ownership $0 1
2020 Ownership $0 1
2019 Ownership $0 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Salvador Peron
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Salvador Peron were reported at $1,780. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Salvador Peron Urology median Middle half National median
2019 $2,452 $480 $147–$1,201 $163
2020 $600 $246 $87–$645 $114
2021 $2,564 $358 $111–$1,000 $132
2022 $2,605 $476 $143–$1,263 $149
2023 $965 $560 $168–$1,461 $160
2024 $3,160 $563 $170–$1,464 $164
2025 $1,780 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Teleflex LLC $4,175 17 payments
  2. Boston Scientific Corporation $1,741 11 payments
  3. Axonics Modulation Technologies, Inc. $1,714 27 payments
  4. Astellas Pharma US Inc $1,089 46 payments
  5. Medtronic, Inc. $1,045 13 payments
  6. Janssen Biotech, Inc. $613 20 payments
  7. Olympus America Inc. $508 10 payments
  8. Pfizer Inc. $281 14 payments
  9. Myovant Sciences Inc. $235 16 payments
  10. Blue Earth Diagnostics Limited $226 9 payments
  11. Other $2,499 114 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,700 275 payments
  2. Travel and Lodging $5,406 13 payments
  3. Education $548 8 payments
  4. Honoraria $473 1 payment
Products named General payments · program years 2019–2025
  1. UROLIFT $2,883 10 payments
  2. Axonics r-SNM System $1,487 15 payments
  3. SOLYX $1,457 7 payments
  4. Bulkamid $866 7 payments
  5. XTANDI $812 42 payments
  6. iTIND System $508 10 payments
  7. ERLEADA $505 19 payments
  8. ORGOVYX $379 23 payments
  9. INTERSTIM $353 10 payments
  10. XIAFLEX $318 20 payments
  11. Other $4,340 185 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

3,479

Median for Urology: 1,053

Drug cost

$265,106

Median for Urology: $101,464

Branded share of claims

14.9%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Orgovyx Relugolix Brand 28 $76,334
Myrbetriq Mirabegron Brand 88 $62,902
Gemtesa Vibegron Brand 41 $39,064
Dutasteride Generic 580 $20,104
Tamsulosin Hcl Generic 921 $12,444
Mirabegron Er Mirabegron Brand 11 $11,038
Silodosin Generic 114 $9,349
Finasteride Generic 384 $4,217
Solifenacin Succinate Generic 89 $3,818
Potassium Citrate Er Potassium Citrate Brand 19 $3,540

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 89 billing codes

Paid by Medicare

$172,958

Of which drugs: $36,736

Medicare patients

460

Average age 75

Services billed

1,837

95 women, 365 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Diabetes 34%
Cancer 33%
Ischemic heart disease 30%
Chronic kidney disease 28%
Atrial fibrillation 23%
Depression 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 27 261 $36,736

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XTANDI
  • Astellas Pharma US Inc $171
  • PFIZER INC. $28
$199 — —
ORGOVYX
  • Sumitomo Pharma America, Inc. $64
  • PFIZER INC. $28
$92 28 —
LUPRON DEPOT
  • AbbVie, Inc. $33
$33 — 261
ERLEADA
  • Janssen Biotech, Inc. $19
$19 — —
LUMRYZ
  • Avadel CNS Pharmaceuticals, LLC $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

297 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record